Dimensional Fund Advisors LP Sells 321,867 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Dimensional Fund Advisors LP decreased its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 15.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,732,378 shares of the company's stock after selling 321,867 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.91% of Caribou Biosciences worth $2,755,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in CRBU. Barclays PLC grew its position in shares of Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company's stock worth $255,000 after buying an additional 71,463 shares in the last quarter. Green Alpha Advisors LLC grew its position in shares of Caribou Biosciences by 75.4% during the 4th quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company's stock worth $288,000 after buying an additional 77,840 shares in the last quarter. Thrive Wealth Management LLC bought a new stake in Caribou Biosciences during the fourth quarter valued at about $51,000. Milestone Asset Management LLC boosted its position in Caribou Biosciences by 5.6% during the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company's stock valued at $260,000 after purchasing an additional 8,662 shares in the last quarter. Finally, US Bancorp DE boosted its position in Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after purchasing an additional 26,467 shares in the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Price Performance

Shares of CRBU stock opened at $0.78 on Wednesday. The stock's 50-day moving average is $0.88 and its 200 day moving average is $1.44. Caribou Biosciences, Inc. has a 1-year low of $0.66 and a 1-year high of $3.91. The company has a market cap of $72.80 million, a P/E ratio of -0.47 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.35 million during the quarter, compared to analysts' expectations of $1.48 million. On average, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $9.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.